Cargando…
Clinical Risk Factors Associated with Anti-Epileptic Drug Responsiveness in Canine Epilepsy
The nature and occurrence of remission, and conversely, pharmacoresistance following epilepsy treatment is still not fully understood in human or veterinary medicine. As such, predicting which patients will have good or poor treatment outcomes is imprecise, impeding patient management. In the presen...
Autores principales: | Packer, Rowena M. A., Shihab, Nadia K., Torres, Bruno B. J., Volk, Holger A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143335/ https://www.ncbi.nlm.nih.gov/pubmed/25153799 http://dx.doi.org/10.1371/journal.pone.0106026 |
Ejemplares similares
-
Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy
por: Packer, Rowena M. A., et al.
Publicado: (2017) -
Assessment into the usage of levetiracetam in a canine epilepsy clinic
por: Packer, Rowena MA, et al.
Publicado: (2015) -
Impact of canine epilepsy on judgement and attention biases
por: Hobbs, Sarah L., et al.
Publicado: (2020) -
Cognitive dysfunction in naturally occurring canine idiopathic epilepsy
por: Packer, Rowena M. A., et al.
Publicado: (2018) -
“We have a ticking time bomb”: a qualitative exploration of the impact of canine epilepsy on dog owners living in England
por: Pergande, Amy E., et al.
Publicado: (2020)